Market Cap
US$1.1b
Last Updated
2019/10/24 00:18 UTC
Data Sources
Company Financials +
Executive Summary
Inogen, Inc., a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally.
Snowflake
Fundamentals
Flawless balance sheet and fair value.
Similar Companies
Share Price & News
How has Inogen's share price performed over time and what events caused price changes?
Latest Share Price and Events
Market Performance
7 Day Return
5.3%
INGN
-1.6%
US Medical Equipment
0.07%
US Market
1 Year Return
-72.8%
INGN
13.8%
US Medical Equipment
8.9%
US Market
Return vs Industry: INGN underperformed the US Medical Equipment industry which returned 13.8% over the past year.
Return vs Market: INGN underperformed the US Market which returned 8.9% over the past year.
Shareholder returns
| INGN | Industry | Market | |
|---|---|---|---|
| 7 Day | 5.3% | -1.6% | 0.07% |
| 30 Day | 8.5% | -4.3% | -0.3% |
| 90 Day | -15.2% | -4.3% | -1.6% |
| 1 Year | -72.8%-72.8% | 14.7%13.8% | 11.3%8.9% |
| 3 Year | 0.6%0.6% | 70.7%65.6% | 46.3%36.8% |
| 5 Year | 117.8%117.8% | 117.3%93.5% | 62.1%44.3% |
Price Volatility Vs. Market
How volatile is Inogen's share price compared to the market and industry in the last 5 years?
Simply Wall St News
5 days ago | Simply Wall St
If You Had Bought Inogen (NASDAQ:INGN) Shares Five Years Ago You'd Have Made 131%2 weeks ago | Simply Wall St
What Is Inogen, Inc.'s (NASDAQ:INGN) Share Price Doing?4 weeks ago | Simply Wall St
Has Inogen, Inc. (NASDAQ:INGN) Improved Earnings Growth In Recent Times?Valuation
Is Inogen undervalued compared to its fair value and its price relative to the market?
6.1%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: INGN ($52.01) is trading below our estimate of fair value ($55.38)
Significantly Below Fair Value: INGN is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: INGN is good value based on its PE Ratio (26.8x) compared to the Medical Equipment industry average (41.8x).
PE vs Market: INGN is poor value based on its PE Ratio (26.8x) compared to the US market (17.8x).
Price to Earnings Growth Ratio
PEG Ratio: INGN is poor value based on its PEG Ratio (1.8x)
Price to Book Ratio
PB vs Industry: INGN is good value based on its PB Ratio (3.4x) compared to the US Medical Equipment industry average (3.7x).
Next Steps
Future Growth
How is Inogen forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
14.8%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: INGN's forecast earnings growth (14.8% per year) is above the savings rate (2.7%).
Earnings vs Market: INGN's earnings (14.8% per year) are forecast to grow faster than the US market (14.5% per year).
High Growth Earnings: INGN's earnings are forecast to grow, but not significantly.
Revenue vs Market: INGN's revenue (9.2% per year) is forecast to grow faster than the US market (7.2% per year).
High Growth Revenue: INGN's revenue (9.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if INGN's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Inogen performed over the past 5 years?
40.6%
Historical annual earnings growth
Earnings and Revenue History
Past Earnings Growth Analysis
Earnings Trend: INGN's earnings have grown significantly by 40.6% per year over the past 5 years.
Accelerating Growth: INGN's earnings growth over the past year (30.7%) is below its 5-year average (40.6% per year).
Earnings vs Industry: INGN earnings growth over the past year (30.7%) exceeded the Medical Equipment industry 28.2%.
Return on Equity
High ROE: INGN's Return on Equity (12.6%) is considered low.
Return on Assets
ROA vs Industry: INGN has a higher Return on Assets than the Medical Equipment industry average last year.
Return on Capital Employed
ROCE Improving: INGN's Return on Capital Employed has declined over the past 3 years.
Next Steps
Financial Health
How is Inogen's financial position?
Financial Position Analysis
Short Term Liabilities: INGN's short term assets ($340.7M) exceeds its short term liabilities ($46.4M)
Long Term Liabilities: INGN's short term assets (340.7M) exceeds its long term liabilities (23.6M)
Debt to Equity History and Analysis
Debt Level: INGN is debt free.
Reducing Debt: INGN has no debt compared to 5 years ago when its debt to equity ratio was 12%.
Debt Coverage: INGN has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: INGN has no debt, therefore coverage of interest payments is not a concern.
Balance Sheet
Inventory Level: INGN has a low level of unsold assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if INGN's debt is covered by short term assets.
Next Steps
Dividend
What is Inogen's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Stability and Growth of Payments
Notable Dividend: Unable to evaluate INGN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate INGN's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stable Dividend: Insufficient data to determine if INGN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if INGN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of INGN's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
What is the CEO of Inogen's salary, the management and board of directors tenure and is there insider trading?
2.8yrs
Average management tenure
CEO
Scott Wilkinson (54yo)
2.6yrs
Tenure
US$2,687,338
Compensation
Mr. Scott Wilkinson has been the Chief Executive Officer of Inogen, Inc. since March 1, 2017 and as its President since January 1, 2016. Mr. Wilkinson served as the Chief Operating Officer of Inogen, Inc. ...
CEO Compensation Analysis
Compensation vs. Market: Scott's total compensation ($USD2.69M) is about average for companies of similar size in the US market ($USD2.67M).
Compensation vs Earnings: Scott's compensation has been consistent with company performance over the past year.
Management Age and Tenure
2.8yrs
Average Tenure
40yo
Average Age
Experienced Management: INGN's management team is considered experienced (2.8 years average tenure).
Board Age and Tenure
5.2yrs
Average Tenure
59yo
Average Age
Experienced Board: INGN's board of directors are considered experienced (5.2 years average tenure).
Insider Trading
Insider Buying: INGN insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
| Entity | Individual |
| Role | Member of the Board of Directors Independent Director |
| Shares | 1,000 |
| Max Price | US$42.93 |
| Entity | Individual |
| Role | Chairman of the Board Independent Chairman of the Board |
| Shares | 2,000 |
| Max Price | US$43.01 |
Ownership Breakdown
Management Team
Brenton Taylor (38yo)
Co-founder & Executive VP of Engineering
- Tenure: 18.8yrs
- Compensation: US$929.83k
Ali Bauerlein (38yo)
Co-founder
- Tenure: 18.8yrs
- Compensation: US$1.24m
Byron Myers (40yo)
Executive Vice President of Sales & Marketing
- Tenure: 2.8yrs
- Compensation: US$928.61k
Scott Wilkinson (54yo)
CEO, President & Director
- Tenure: 2.6yrs
- Compensation: US$2.69m
Bart Sanford (53yo)
Executive Vice President of Operations
- Tenure: 1.1yrs
- Compensation: US$1.15m
Matt Bacso
Investor Relations & Corporate Development Manager
- Tenure: 0yrs
Board Members
R. Greer (61yo)
Independent Director
- Tenure: 4.2yrs
- Compensation: US$240.74k
Heath Lukatch (52yo)
Independent Chairman of the Board
- Tenure: 11.8yrs
- Compensation: US$296.24k
Richard Casaburi
Member of Advisory Board
- Tenure: 0yrs
Jeffrey Kupperman
Member of Advisory Board
- Tenure: 0yrs
Paul Selecky
Member of Advisory Board
- Tenure: 0yrs
Neil MacIntyre
Member of Advisory Board
- Tenure: 0yrs
Loren McFarland (60yo)
Independent Director
- Tenure: 6.8yrs
- Compensation: US$236.24k
Scott Wilkinson (54yo)
CEO, President & Director
- Tenure: 2.6yrs
- Compensation: US$2.69m
Robert Chatburn
Member of Advisory Board
- Tenure: 0yrs
Heather Rider (59yo)
Independent Director
- Tenure: 5.2yrs
- Compensation: US$240.24k
Company Information
Inogen, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Inogen, Inc.
- Ticker: INGN
- Exchange: NasdaqGS
- Founded: 2001
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$1.141b
- Shares outstanding: 21.93m
- Website: https://www.inogen.com
Number of Employees
Location
- Inogen, Inc.
- 326 Bollay Drive
- Goleta
- California
- 93117
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| INGN | NasdaqGS (Nasdaq Global Select) | Yes | Common Stock | US | USD | Feb 2014 |
| 6IO | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Feb 2014 |
Biography
Inogen, Inc., a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United S ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/10/24 00:18 |
| End of Day Share Price | 2019/10/23 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.